Bayram, NihanYaman, YöntemÖzdilli, KürşatTelhan, LeylaNepesov, SerdarBilgen, HülyaElli, MuratBehar, Sude SemaAnak, Sema2021-10-112021-10-112021Bayram, N., Yaman, Y., Özdilli, K., Telhan, L., Nepesov, S., Bilgen, H. ... Anak, S. (2021). Clinical efficacy of ruxolitinib monotherapy and haploidentical hematopoeitic stem cell transplantation in a child with philadelphia chromosome-like relapsed/refractory acute lymphoblastic leukemia. Pediatric Transplantation, 25(4). https://dx.doi.org/10.1111/petr.140241397-31421399-3046https://dx.doi.org/10.1111/petr.14024https://hdl.handle.net/20.500.12511/8410Introduction (Ph-like) ALL is a subset of leukemia which has a gene expression profile similar to Ph+disease, but without the presence of BCR-ABL1 translocation. Case description We reported an exceptional case of a child with relapsed Ph-like ALL with IKZF1 gene deletion treated with high-dose ruxolitinib as monotherapy, after multi-agent chemotherapy. He remains in continued MRD-negative leukemia remission with full donor chimerism at 12 months post-HSCT. Discussion The circumstance that makes our case featured is the usage of ruxolitinib as monotherapy. This report, we believe, is a pioneering report for a frequent disease with a high risk of failure for the outcome.eninfo:eu-repo/semantics/embargoedAccessJAK InhibitorsPhiladelphia-Like ALLRefractory ALLStem Cell TransplantationArticle25410.1111/petr.14024Q4Q2